Evaluation of compounded bevacizumab prepared for intravitreal injection

Nicolas A. Yannuzzi, Michael A. Klufas, Lucy Quach, Lauren M. Beatty, Stephen M. Kaminsky, Ronald Crystal, Donald J. D'Amico, Szilárd Kiss

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

IMPORTANCE: Bevacizumab acquired from compounding pharmacies for intravitreal injection may cause infectious and noninfectious inflammation. In addition to safety issues, the drug itself may have variable efficacy associated with product aliquoting, handling, and distribution. OBJECTIVE: To conduct surveillance cultures, evaluate endotoxin levels, and assess protein concentrations of bevacizumab obtained from compounding pharmacies in the United States. DESIGN AND SETTING: Prospective in vitro study of syringes containing intravitreal preparations of bevacizumab from compounding pharmacies. This study was conducted at a university-based, good manufacturing practice facility and academic ophthalmology practice. MAIN OUTCOMES AND MEASURES: Microbial culture growth, endotoxin levels, and quantity and binding affinity of protein in each sample. RESULTS: There were no microbial contaminants or endotoxin detected in any of the samples. Of the 21 compounded samples of bevacizumab obtained from 11 pharmacies, 17 (81%) had lower protein concentrations (mean [SD], 22.2 [4.9]mg/mL; range, 19.2-24.5mg/mL) compared with bevacizumab acquired directly from Genentech (25mg/mL; P 〈 .05). In 3 of 10 compounding pharmacies where more than 1 sample was available, there were statistically significant differences in the protein concentration between samples from the same compounding pharmacy. CONCLUSIONS AND RELEVANCE: Test results from intravitreal preparations of bevacizumab acquired from compounding pharmacies were negative for microbial contaminants and endotoxin. However, there were significant variations in protein concentration that appear in general to be lower than bevacizumab acquired directly from Genentech. The clinical implications of these variable protein levels remain uncertain.

Original languageEnglish
Pages (from-to)32-39
Number of pages8
JournalJAMA Ophthalmology
Volume133
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015
Externally publishedYes

Fingerprint

Intravitreal Injections
Pharmacies
Endotoxins
Proteins
Syringes
Ophthalmology
Bevacizumab
Carrier Proteins
Inflammation
Safety
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Yannuzzi, N. A., Klufas, M. A., Quach, L., Beatty, L. M., Kaminsky, S. M., Crystal, R., ... Kiss, S. (2015). Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmology, 133(1), 32-39. https://doi.org/10.1001/jamaophthalmol.2014.3591

Evaluation of compounded bevacizumab prepared for intravitreal injection. / Yannuzzi, Nicolas A.; Klufas, Michael A.; Quach, Lucy; Beatty, Lauren M.; Kaminsky, Stephen M.; Crystal, Ronald; D'Amico, Donald J.; Kiss, Szilárd.

In: JAMA Ophthalmology, Vol. 133, No. 1, 01.01.2015, p. 32-39.

Research output: Contribution to journalArticle

Yannuzzi, NA, Klufas, MA, Quach, L, Beatty, LM, Kaminsky, SM, Crystal, R, D'Amico, DJ & Kiss, S 2015, 'Evaluation of compounded bevacizumab prepared for intravitreal injection', JAMA Ophthalmology, vol. 133, no. 1, pp. 32-39. https://doi.org/10.1001/jamaophthalmol.2014.3591
Yannuzzi, Nicolas A. ; Klufas, Michael A. ; Quach, Lucy ; Beatty, Lauren M. ; Kaminsky, Stephen M. ; Crystal, Ronald ; D'Amico, Donald J. ; Kiss, Szilárd. / Evaluation of compounded bevacizumab prepared for intravitreal injection. In: JAMA Ophthalmology. 2015 ; Vol. 133, No. 1. pp. 32-39.
@article{27134bcc0cc24e86983718b2c8ac77f8,
title = "Evaluation of compounded bevacizumab prepared for intravitreal injection",
abstract = "IMPORTANCE: Bevacizumab acquired from compounding pharmacies for intravitreal injection may cause infectious and noninfectious inflammation. In addition to safety issues, the drug itself may have variable efficacy associated with product aliquoting, handling, and distribution. OBJECTIVE: To conduct surveillance cultures, evaluate endotoxin levels, and assess protein concentrations of bevacizumab obtained from compounding pharmacies in the United States. DESIGN AND SETTING: Prospective in vitro study of syringes containing intravitreal preparations of bevacizumab from compounding pharmacies. This study was conducted at a university-based, good manufacturing practice facility and academic ophthalmology practice. MAIN OUTCOMES AND MEASURES: Microbial culture growth, endotoxin levels, and quantity and binding affinity of protein in each sample. RESULTS: There were no microbial contaminants or endotoxin detected in any of the samples. Of the 21 compounded samples of bevacizumab obtained from 11 pharmacies, 17 (81{\%}) had lower protein concentrations (mean [SD], 22.2 [4.9]mg/mL; range, 19.2-24.5mg/mL) compared with bevacizumab acquired directly from Genentech (25mg/mL; P 〈 .05). In 3 of 10 compounding pharmacies where more than 1 sample was available, there were statistically significant differences in the protein concentration between samples from the same compounding pharmacy. CONCLUSIONS AND RELEVANCE: Test results from intravitreal preparations of bevacizumab acquired from compounding pharmacies were negative for microbial contaminants and endotoxin. However, there were significant variations in protein concentration that appear in general to be lower than bevacizumab acquired directly from Genentech. The clinical implications of these variable protein levels remain uncertain.",
author = "Yannuzzi, {Nicolas A.} and Klufas, {Michael A.} and Lucy Quach and Beatty, {Lauren M.} and Kaminsky, {Stephen M.} and Ronald Crystal and D'Amico, {Donald J.} and Szil{\'a}rd Kiss",
year = "2015",
month = "1",
day = "1",
doi = "10.1001/jamaophthalmol.2014.3591",
language = "English",
volume = "133",
pages = "32--39",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Evaluation of compounded bevacizumab prepared for intravitreal injection

AU - Yannuzzi, Nicolas A.

AU - Klufas, Michael A.

AU - Quach, Lucy

AU - Beatty, Lauren M.

AU - Kaminsky, Stephen M.

AU - Crystal, Ronald

AU - D'Amico, Donald J.

AU - Kiss, Szilárd

PY - 2015/1/1

Y1 - 2015/1/1

N2 - IMPORTANCE: Bevacizumab acquired from compounding pharmacies for intravitreal injection may cause infectious and noninfectious inflammation. In addition to safety issues, the drug itself may have variable efficacy associated with product aliquoting, handling, and distribution. OBJECTIVE: To conduct surveillance cultures, evaluate endotoxin levels, and assess protein concentrations of bevacizumab obtained from compounding pharmacies in the United States. DESIGN AND SETTING: Prospective in vitro study of syringes containing intravitreal preparations of bevacizumab from compounding pharmacies. This study was conducted at a university-based, good manufacturing practice facility and academic ophthalmology practice. MAIN OUTCOMES AND MEASURES: Microbial culture growth, endotoxin levels, and quantity and binding affinity of protein in each sample. RESULTS: There were no microbial contaminants or endotoxin detected in any of the samples. Of the 21 compounded samples of bevacizumab obtained from 11 pharmacies, 17 (81%) had lower protein concentrations (mean [SD], 22.2 [4.9]mg/mL; range, 19.2-24.5mg/mL) compared with bevacizumab acquired directly from Genentech (25mg/mL; P 〈 .05). In 3 of 10 compounding pharmacies where more than 1 sample was available, there were statistically significant differences in the protein concentration between samples from the same compounding pharmacy. CONCLUSIONS AND RELEVANCE: Test results from intravitreal preparations of bevacizumab acquired from compounding pharmacies were negative for microbial contaminants and endotoxin. However, there were significant variations in protein concentration that appear in general to be lower than bevacizumab acquired directly from Genentech. The clinical implications of these variable protein levels remain uncertain.

AB - IMPORTANCE: Bevacizumab acquired from compounding pharmacies for intravitreal injection may cause infectious and noninfectious inflammation. In addition to safety issues, the drug itself may have variable efficacy associated with product aliquoting, handling, and distribution. OBJECTIVE: To conduct surveillance cultures, evaluate endotoxin levels, and assess protein concentrations of bevacizumab obtained from compounding pharmacies in the United States. DESIGN AND SETTING: Prospective in vitro study of syringes containing intravitreal preparations of bevacizumab from compounding pharmacies. This study was conducted at a university-based, good manufacturing practice facility and academic ophthalmology practice. MAIN OUTCOMES AND MEASURES: Microbial culture growth, endotoxin levels, and quantity and binding affinity of protein in each sample. RESULTS: There were no microbial contaminants or endotoxin detected in any of the samples. Of the 21 compounded samples of bevacizumab obtained from 11 pharmacies, 17 (81%) had lower protein concentrations (mean [SD], 22.2 [4.9]mg/mL; range, 19.2-24.5mg/mL) compared with bevacizumab acquired directly from Genentech (25mg/mL; P 〈 .05). In 3 of 10 compounding pharmacies where more than 1 sample was available, there were statistically significant differences in the protein concentration between samples from the same compounding pharmacy. CONCLUSIONS AND RELEVANCE: Test results from intravitreal preparations of bevacizumab acquired from compounding pharmacies were negative for microbial contaminants and endotoxin. However, there were significant variations in protein concentration that appear in general to be lower than bevacizumab acquired directly from Genentech. The clinical implications of these variable protein levels remain uncertain.

UR - http://www.scopus.com/inward/record.url?scp=84920971127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920971127&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2014.3591

DO - 10.1001/jamaophthalmol.2014.3591

M3 - Article

C2 - 25233052

AN - SCOPUS:84920971127

VL - 133

SP - 32

EP - 39

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 1

ER -